Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study
Non small cell lung carcinoma; Chemotherapy; microRNA; Response prediction; Prognosis; Survival
Abstract :
[en] Clinical variables, like stage and performance status (PS), have predictive and prognostic values in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy, not allowing adequate individual prediction. MicroRNA (miRNA) are non-coding RNAs regulating gene expression. In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. miRNA expression was analysed on a biopsy obtained during the diagnostic bronchoscopy, using TaqMan Low Density Arrays. The signature for response was derived using logistic regression with stepwise variable selection. The associations between overall survival and miRNA expression levels were estimated by using the Kaplan–Meier method, log-rank test, and Cox proportional hazard regression models to estimate the hazard ratios. In total, 38 patients with adequate tumour biopsies, treated with cisplatin-vinorelbine were included: male (n = 27), 80–100 Karnofsky PS (n = 27), adenocarcinoma (n = 20), stage IV (n = 30). One patient was considered not assessable for response but remained included in the survival analyses. Out of the 37 patients assessable for response, 16 partial responses (43%) were observed. A two miRNA signature (miR-149 and miR-375) was found predictive for response and was also associated to progression-free survival (p = 0.05). Using a linear combination of the miR CT values with Cox’s regression coefficients as weights, we constructed a prognostic score for overall survival including four miRNA (miR-200c, miR-424, miR-29c and miR-124). The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8–52.4) and 15.5 months (95% CI 9.1–22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7–94.9). Conclusions: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine.
Disciplines :
Oncology
Author, co-author :
Berghmans, T
Ameye, L
Willems, Luc ; Université de Liège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Biologie cell. et moléc.
Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study
Publication date :
2013
Journal title :
Lung Cancer
ISSN :
0169-5002
eISSN :
1872-8332
Publisher :
Elsevier Scientific, Limerick, Ireland
Volume :
82
Pages :
340-345
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE] Télévie [BE]
Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(August (8)):706-714.
Alexopoulos A., Alard S., Berghmans T., Berchier M.C., Bonduelle Y., Colinet, et al. European Lung Cancer Working Party Clinical Practice Guidelines: clinical practice guidelines, non-small cell lung cancer: III. Metastatic disease. Hospital Chronicles 2008, 1(3):169-185.
Levine M., Browman G., Newman T., Cowan D.H. The Ontario cancer treatment practice guidelines initiative. Oncology (Williston Park) 1996, 10(November (11 Suppl.)):19-22.
Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(January (2)):330-353.
Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(September (3 Suppl.)):277S-289S.
Yu Y., Xu X., Du Z., Shi M. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer Chemother Pharmacol 2012, 69(May (5)):1265-1275.
Petrelli F., Borgonovo K., Cabiddu M., Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13(March (2)):107-114.
Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(October (10)):1011-1019.
Jiang J., Liang X., Zhou X., Huang R., Chu Z., Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 2012, 39(June (6)):6933-6942.
Gong W., Zhang X., Wu J., Chen L., Li L., Sun J., et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012, 75(March (3)):374-380.
Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(July (19)):2747-2754.
Bian H.B., Pan X., Yang J.S., Wang Z.X., De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011, 30:20.
Ceppi P., Mudduluru G., Kumarswamy R., Rapa I., Scagliotti G.V., Papotti M., et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010, 8(September (9)):1207-1216.
Enfield K.S., Stewart G.L., Pikor L.A., Alvarez C.E., Lam S., Lam W.L., et al. MicroRNA gene dosage alterations and drug response in lung cancer. J Biomed Biotechnol 2011, 2011:474632.
Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70(March (5)):1793-1803.
Wang Q., Zhong M., Liu W., Li J., Huang J., Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011, 37(September (7)):427-434.
Zhang S., Zhang C., Li Y., Wang P., Yue Z., Xie S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 2011, 65(September (6)):436-442.
Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(December (11)):2520-2529.
Ranade A.R., Cherba D., Sridhar S., Richardson P., Webb C., Paripati A., et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010, 5(August (8)):1273-1278.
WHO handbook for reporting results of cancer treatment. WHO offset publication n°48, Geneva; 1979.
Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9(July (7)):811-818.
Donnem T., Lonvik K., Eklo K., Berg T., Sorbye S.W., Al-Shibli K., et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011, 117(July (14)):3193-3200.
Donnem T., Eklo K., Berg T., Sorbye S.W., Lonvik K., Al-Saad S., et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011, 9:6.
Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28(April (10)):1721-1726.
Landi M.T., Zhao Y., Rotunno M., Koshiol J., Liu H., Bergen A.W., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16(January (2)):430-441.
Markou A., Tsaroucha E.G., Kaklamanis L., Fotinou M., Georgoulias V., Lianidou E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008, 54(October (10)):1696-1704.
Raponi M., Dossey L., Jatkoe T., Wu X., Chen G., Fan H., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69(July (14)):5776-5783.
Saito M., Schetter A.J., Mollerup S., Kohno T., Skaug V., Bowman E.D., et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011, 17(April (7)):1875-1882.
Tan X., Qin W., Zhang L., Hang J., Li B., Zhang C., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011, 17(November (21)):6802-6811.
Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13(January (1)):48-57.
Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(March (3)):189-198.
Jin L., Hu W.L., Jiang C.C., Wang J.X., Han C.C., Chu P., et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A 2011, 108(September (38)):15840-15845.
Luo Z., Zhang L., Li Z., Jiang C., Dai Y., Liu X., et al. miR-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011, 36(July (7)):604-609.
Nishikawa E., Osada H., Okazaki Y., Arima C., Tomida S., Tatematsu Y., et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res 2011, 71(October (19)):6165-6173.
Zhao H., Zhu L., Jin Y., Ji H., Yan X., Zhu X. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2012, 44(February (2)):177-182.
Kinoshita T., Nohata N., Yoshino H., Hanazawa T., Kikkawa N., Fujimura L., et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol 2012, 40(January (1)):185-193.
Hui A.B., Bruce J.P., Alajez N.M., Shi W., Yue S., Perez-Ordonez B., et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 2011, 17(December (24)):7539-7550.
Harris T., Jimenez L., Kawachi N., Fan J.B., Chen J., Belbin T., et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012, 180(March (3)):917-928.
Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61(January (1)):33-42.
Zhang X., Yan Z., Zhang J., Gong L., Li W., Cui J., et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011, 22(October (10)):2257-2266.
Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8(May (5)):1055-1066.
Liu X.G., Zhu W.Y., Huang Y.Y., Ma L.N., Zhou S.Q., Wang Y.K., et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012, 29(June (2)):618-626.
Xu Y., Brenn T., Brown E.R., Doherty V., Melton D.W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012, 106(January (3)):553-561.
Ding D.P., Chen Z.L., Zhao X.H., Wang J.W., Sun J., Wang Z., et al. miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 2011, 32(July (7)):1025-1032.
Zheng F., Liao Y.J., Cai M.Y., Liu Y.H., Liu T.H., Chen S.P., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61(February (2)):278-289.
Nakashima T., Jinnin M., Etoh T., Fukushima S., Masuguchi S., Maruo K., et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One 2010, 5(12):e14334.
Wang X.C., Du L.Q., Tian L.L., Wu H.L., Jiang X.Y., Zhang H., et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 2011, 72(April (1)):92-99.
Mascaux C., Laes J.F., Anthoine G., Haller A., Ninane V., Burny A., et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 2009, 33(February (2)):352-359.
Hoang T., Dahlberg S.E., Schiller J.H., Johnson D.H. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer 2013, 81(July (1)):47-52.